FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2590953389> ?p ?o ?g. }

• W2590953389 endingPage "26184" @default.
• W2590953389 startingPage "26169" @default.
• W2590953389 abstract "// Helga Weber 1, 2, * , José R. Valbuena 3, * , Mustafa A. Barbhuiya 4 , Stefan Stein 5 , Hana Kunkel 5 , Patricia García 3, 6 , Carolina Bizama 3, 6 , Ismael Riquelme 1, 2 , Jaime A. Espinoza 7 , Stephen E. Kurtz 8 , Jeffrey W. Tyner 8 , Juan Francisco Calderon 9 , Alejandro H. Corvalán 6, 10 , Manuel Grez 5 , Akhilesh Pandey 4, 11 , Pamela Leal-Rojas 1 , Juan C. Roa 3, 6 1 Center of Excellence in Traslational Medicine (CEMT) and Scientific and Technological Bioresource Nucleus (BIOREN), Universidad de La Frontera, Temuco, Chile 2 Department of Pathology, Faculty of Medicine, Temuco, Chile 3 Department of Pathology, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile 4 McKusick-Nathans Institute of Genetic Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD, USA 5 Gene Therapy Unit, Institute for Tumor Biology and Experimental Therapy, Georg-Speyer-Haus, Frankfurt, Germany 6 Center for Investigation in Translational Oncology (CITO), Advanced Center for Chronic Diseases (ACCDiS), Millennium Institute on Immunology and Immunotherapy, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile 7 SciLifeLab, Division of Genome Biology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Solna, Stockholm, Sweden 8 Division of Hematology and Medical Oncology, Cell, Developmental and Cancer Biology, Oregon Health and Science University, Portland, OR, USA 9 Center for Genetics and Genomics, School of Medicine, Clínica Alemana de Santiago - Universidad del Desarrollo, Santiago, Chile 10 Department of Hematology Oncology, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile 11 Department of Biological Chemistry, Department of Oncology, Department of Pathology, The Johns Hopkins University School of Medicine Baltimore, MD, USA * These authors contributed equally to this work Correspondence to: Juan C. Roa, email: jcroa@med.puc.cl Pamela Leal-Rojas, email: pamela.leal@ufrontera.cl Keywords: gallbladder cancer, HSP90 inhibitors, geldanamycin, 17-AAG, gallbladder cancer xenografts Received: October 13, 2016      Accepted: February 01, 2017      Published: February 16, 2017 ABSTRACT Gallbladder cancer (GBC) is a lethal cancer with poor prognosis associated with high invasiveness and poor response to chemotherapy and radiotherapy. New therapeutic approaches are urgently needed in order to improve survival and response rates of GBC patients. We screened 130 small molecule inhibitors on a panel of seven GBC cell lines and identified the HSP90 inhibitor 17-AAG as one of the most potent inhibitory drugs across the different lines. We tested the antitumor efficacy of 17-AAG and geldanamycin (GA) in vitro and in a subcutaneous preclinical tumor model NOD-SCID mice. We also evaluated the expression of HSP90 by immunohistochemistry in human GBC tumors. In vitro assays showed that 17-AAG and GA significantly reduced the expression of HSP90 target proteins, including EGFR, AKT, phospho-AKT, Cyclin B1, phospho-ERK and Cyclin D1. These molecular changes were consistent with reduced cell viability and cell migration and promotion of G2/M cell cycle arrest and apoptosis observed in our in vitro studies. In vivo , 17-AAG showed efficacy in reducing subcutaneous tumors size, exhibiting a 69.6% reduction in tumor size in the treatment group compared to control mice ( p < 0.05). The HSP90 immunohistochemical staining was seen in 182/209 cases of GBC (87%) and it was strongly expressed in 70 cases (33%), moderately in 58 cases (28%), and weakly in 54 cases (26%). Our pre-clinical observations strongly suggest that the inhibition of HSP90 function by HSP90 inhibitors is a promising therapeutic strategy for gallbladder cancer that may benefit from new HSP90 inhibitors currently in development." @default.
• W2590953389 created "2017-03-03" @default.
• W2590953389 creator A5001965184 @default.
• W2590953389 creator A5014553335 @default.
• W2590953389 creator A5034862403 @default.
• W2590953389 creator A5040937658 @default.
• W2590953389 creator A5042652838 @default.
• W2590953389 creator A5050852442 @default.
• W2590953389 creator A5051731460 @default.
• W2590953389 creator A5052399625 @default.
• W2590953389 creator A5053052105 @default.
• W2590953389 creator A5058340446 @default.
• W2590953389 creator A5058959499 @default.
• W2590953389 creator A5068779716 @default.
• W2590953389 creator A5069929247 @default.
• W2590953389 creator A5070009317 @default.
• W2590953389 creator A5071989602 @default.
• W2590953389 creator A5075070858 @default.
• W2590953389 creator A5091457383 @default.
• W2590953389 date "2017-02-16" @default.
• W2590953389 modified "2023-09-30" @default.
• W2590953389 title "Small molecule inhibitor screening identifified HSP90 inhibitor 17-AAG as potential therapeutic agent for gallbladder cancer" @default.
• W2590953389 cites W1563031684 @default.
• W2590953389 cites W169561243 @default.
• W2590953389 cites W1965491811 @default.
• W2590953389 cites W1965959593 @default.
• W2590953389 cites W1966373529 @default.
• W2590953389 cites W1966703064 @default.
• W2590953389 cites W1973328141 @default.
• W2590953389 cites W1976523749 @default.
• W2590953389 cites W1976681308 @default.
• W2590953389 cites W1981051246 @default.
• W2590953389 cites W1984789674 @default.
• W2590953389 cites W1986537426 @default.
• W2590953389 cites W1987325617 @default.
• W2590953389 cites W1987981239 @default.
• W2590953389 cites W1988675578 @default.
• W2590953389 cites W1995744351 @default.
• W2590953389 cites W1998897461 @default.
• W2590953389 cites W2000929246 @default.
• W2590953389 cites W2007649418 @default.
• W2590953389 cites W2008308510 @default.
• W2590953389 cites W2017357396 @default.
• W2590953389 cites W2020240443 @default.
• W2590953389 cites W2022354852 @default.
• W2590953389 cites W2023349699 @default.
• W2590953389 cites W2025550489 @default.
• W2590953389 cites W2028163699 @default.
• W2590953389 cites W2034097803 @default.
• W2590953389 cites W2054186713 @default.
• W2590953389 cites W2058970657 @default.
• W2590953389 cites W2060902443 @default.
• W2590953389 cites W2069828527 @default.
• W2590953389 cites W2074579328 @default.
• W2590953389 cites W2075805324 @default.
• W2590953389 cites W2077711052 @default.
• W2590953389 cites W2087684358 @default.
• W2590953389 cites W2096814137 @default.
• W2590953389 cites W2098480759 @default.
• W2590953389 cites W2104706142 @default.
• W2590953389 cites W2108015399 @default.
• W2590953389 cites W2108756633 @default.
• W2590953389 cites W2125123239 @default.
• W2590953389 cites W2132580929 @default.
• W2590953389 cites W2132664329 @default.
• W2590953389 cites W2133554539 @default.
• W2590953389 cites W2141859437 @default.
• W2590953389 cites W2141956720 @default.
• W2590953389 cites W2159776731 @default.
• W2590953389 cites W2171708713 @default.
• W2590953389 cites W2180914302 @default.
• W2590953389 cites W2187584967 @default.
• W2590953389 cites W2201245685 @default.
• W2590953389 cites W2349304676 @default.
• W2590953389 cites W2406097091 @default.
• W2590953389 cites W275026060 @default.
• W2590953389 cites W4210407906 @default.
• W2590953389 cites W2312760783 @default.
• W2590953389 doi "https://doi.org/10.18632/oncotarget.15410" @default.
• W2590953389 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5432248" @default.
• W2590953389 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28412732" @default.
• W2590953389 hasPublicationYear "2017" @default.
• W2590953389 type Work @default.
• W2590953389 sameAs 2590953389 @default.
• W2590953389 citedByCount "22" @default.
• W2590953389 countsByYear W25909533892018 @default.
• W2590953389 countsByYear W25909533892019 @default.
• W2590953389 countsByYear W25909533892020 @default.
• W2590953389 countsByYear W25909533892021 @default.
• W2590953389 countsByYear W25909533892022 @default.
• W2590953389 countsByYear W25909533892023 @default.
• W2590953389 crossrefType "journal-article" @default.
• W2590953389 hasAuthorship W2590953389A5001965184 @default.
• W2590953389 hasAuthorship W2590953389A5014553335 @default.
• W2590953389 hasAuthorship W2590953389A5034862403 @default.
• W2590953389 hasAuthorship W2590953389A5040937658 @default.
• W2590953389 hasAuthorship W2590953389A5042652838 @default.
• W2590953389 hasAuthorship W2590953389A5050852442 @default.

• next